Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Cholesterol-conjugated stapled peptides inhibit Ebola and Marburg viruses in vitro and in vivo.

Pessi A, Bixler SL, Soloveva V, Radoshitzky S, Retterer C, Kenny T, Zamani R, Gomba G, Gharabeih D, Wells J, Wetzel KS, Warren TK, Donnelly G, Van Tongeren SA, Steffens J, Duplantier AJ, Kane CD, Vicat P, Couturier V, Kester KE, Shiver J, Carter K, Bavari S.

Antiviral Res. 2019 Nov;171:104592. doi: 10.1016/j.antiviral.2019.104592. Epub 2019 Aug 29.

2.

Characterization of the plasma proteome of nonhuman primates during Ebola virus disease or melioidosis: a host response comparison.

Ward MD, Brueggemann EE, Kenny T, Reitstetter RE, Mahone CR, Trevino S, Wetzel K, Donnelly GC, Retterer C, Norgren RB Jr, Panchal RG, Warren TK, Bavari S, Cazares LH.

Clin Proteomics. 2019 Feb 7;16:7. doi: 10.1186/s12014-019-9227-3. eCollection 2019.

3.

Virulence of Marburg Virus Angola Compared to Mt. Elgon (Musoke) in Macaques: A Pooled Survival Analysis.

Blair PW, Keshtkar-Jahromi M, Psoter KJ, Reisler RB, Warren TK, Johnston SC, Goff AJ, Downey LG, Bavari S, Cardile AP.

Viruses. 2018 Nov 21;10(11). pii: E658. doi: 10.3390/v10110658.

4.

Ebola Virus Causes Intestinal Tract Architectural Disruption and Bacterial Invasion in Non-Human Primates.

Reisler RB, Zeng X, Schellhase CW, Bearss JJ, Warren TK, Trefry JC, Christopher GW, Kortepeter MG, Bavari S, Cardile AP.

Viruses. 2018 Sep 20;10(10). pii: E513. doi: 10.3390/v10100513.

5.

Persistent Marburg Virus Infection in the Testes of Nonhuman Primate Survivors.

Coffin KM, Liu J, Warren TK, Blancett CD, Kuehl KA, Nichols DK, Bearss JJ, Schellhase CW, Retterer CJ, Weidner JM, Radoshitzky SR, Brannan JM, Cardile AP, Dye JM, Palacios G, Sun MG, Kuhn JH, Bavari S, Zeng X.

Cell Host Microbe. 2018 Sep 12;24(3):405-416.e3. doi: 10.1016/j.chom.2018.08.003. Epub 2018 Aug 30.

6.

Efficacy of favipiravir (T-705) in nonhuman primates infected with Ebola virus or Marburg virus.

Bixler SL, Bocan TM, Wells J, Wetzel KS, Van Tongeren SA, Dong L, Garza NL, Donnelly G, Cazares LH, Nuss J, Soloveva V, Koistinen KA, Welch L, Epstein C, Liang LF, Giesing D, Lenk R, Bavari S, Warren TK.

Antiviral Res. 2018 Mar;151:97-104. doi: 10.1016/j.antiviral.2017.12.021. Epub 2017 Dec 28.

7.

Intracellular conversion and in vivo dose response of favipiravir (T-705) in rodents infected with Ebola virus.

Bixler SL, Bocan TM, Wells J, Wetzel KS, Van Tongeren SA, Garza NL, Donnelly G, Cazares LH, Soloveva V, Welch L, Epstein C, Liang LF, Giesing D, Lenk R, Bavari S, Warren TK.

Antiviral Res. 2018 Mar;151:50-54. doi: 10.1016/j.antiviral.2017.12.020. Epub 2017 Dec 28.

8.

Clinical Laboratory Values as Early Indicators of Ebola Virus Infection in Nonhuman Primates.

Reisler RB, Yu C, Donofrio MJ, Warren TK, Wells JB, Stuthman KS, Garza NL, Vantongeren SA, Donnelly GC, Kane CD, Kortepeter MG, Bavari S, Cardile AP.

Emerg Infect Dis. 2017 Aug;23(8):1316-1324. doi: 10.3201/eid2308.170029.

9.

Identification and pathological characterization of persistent asymptomatic Ebola virus infection in rhesus monkeys.

Zeng X, Blancett CD, Koistinen KA, Schellhase CW, Bearss JJ, Radoshitzky SR, Honnold SP, Chance TB, Warren TK, Froude JW, Cashman KA, Dye JM, Bavari S, Palacios G, Kuhn JH, Sun MG.

Nat Microbiol. 2017 Jul 17;2:17113. doi: 10.1038/nmicrobiol.2017.113.

PMID:
28715405
10.

Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses.

Siegel D, Hui HC, Doerffler E, Clarke MO, Chun K, Zhang L, Neville S, Carra E, Lew W, Ross B, Wang Q, Wolfe L, Jordan R, Soloveva V, Knox J, Perry J, Perron M, Stray KM, Barauskas O, Feng JY, Xu Y, Lee G, Rheingold AL, Ray AS, Bannister R, Strickley R, Swaminathan S, Lee WA, Bavari S, Cihlar T, Lo MK, Warren TK, Mackman RL.

J Med Chem. 2017 Mar 9;60(5):1648-1661. doi: 10.1021/acs.jmedchem.6b01594. Epub 2017 Feb 14.

PMID:
28124907
11.

Detection of Ebola Virus RNA Through Aerosol Sampling of Animal Biosafety Level 4 Rooms Housing Challenged Nonhuman Primates.

Harbourt DE, Johnston SC, Pettitt J, Warren TK, Dorman WR.

J Infect Dis. 2017 Feb 15;215(4):554-558. doi: 10.1093/infdis/jiw610.

PMID:
28011922
12.

Will There Be a Cure for Ebola?

Cardile AP, Warren TK, Martins KA, Reisler RB, Bavari S.

Annu Rev Pharmacol Toxicol. 2017 Jan 6;57:329-348. doi: 10.1146/annurev-pharmtox-010716-105055. Epub 2016 Dec 7. Review.

PMID:
27959624
13.

Assessment of the potential for host-targeted iminosugars UV-4 and UV-5 activity against filovirus infections in vitro and in vivo.

Warfield KL, Warren TK, Qiu X, Wells J, Mire CE, Geisbert JB, Stuthman KS, Garza NL, Van Tongeren SA, Shurtleff AC, Agans KN, Wong G, Callahan MV, Geisbert TW, Klose B, Ramstedt U, Treston AM.

Antiviral Res. 2017 Feb;138:22-31. doi: 10.1016/j.antiviral.2016.11.019. Epub 2016 Nov 28.

PMID:
27908828
14.

Antiviral therapeutics for the treatment of Ebola virus infection.

Cardile AP, Downey LG, Wiseman PD, Warren TK, Bavari S.

Curr Opin Pharmacol. 2016 Oct;30:138-143. doi: 10.1016/j.coph.2016.08.016. Review.

PMID:
27639220
15.

Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys.

Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, Siegel D, Perron M, Bannister R, Hui HC, Larson N, Strickley R, Wells J, Stuthman KS, Van Tongeren SA, Garza NL, Donnelly G, Shurtleff AC, Retterer CJ, Gharaibeh D, Zamani R, Kenny T, Eaton BP, Grimes E, Welch LS, Gomba L, Wilhelmsen CL, Nichols DK, Nuss JE, Nagle ER, Kugelman JR, Palacios G, Doerffler E, Neville S, Carra E, Clarke MO, Zhang L, Lew W, Ross B, Wang Q, Chun K, Wolfe L, Babusis D, Park Y, Stray KM, Trancheva I, Feng JY, Barauskas O, Xu Y, Wong P, Braun MR, Flint M, McMullan LK, Chen SS, Fearns R, Swaminathan S, Mayers DL, Spiropoulou CF, Lee WA, Nichol ST, Cihlar T, Bavari S.

Nature. 2016 Mar 17;531(7594):381-5. doi: 10.1038/nature17180. Epub 2016 Mar 2. Erratum in: ACS Chem Biol. 2016 May 20;11(5):1463.

16.

Delayed Time-to-Treatment of an Antisense Morpholino Oligomer Is Effective against Lethal Marburg Virus Infection in Cynomolgus Macaques.

Warren TK, Whitehouse CA, Wells J, Welch L, Charleston JS, Heald A, Nichols DK, Mattix ME, Palacios G, Kugleman JR, Iversen PL, Bavari S.

PLoS Negl Trop Dis. 2016 Feb 22;10(2):e0004456. doi: 10.1371/journal.pntd.0004456. eCollection 2016 Feb.

17.

AVI-7288 for Marburg Virus in Nonhuman Primates and Humans.

Heald AE, Charleston JS, Iversen PL, Warren TK, Saoud JB, Al-Ibrahim M, Wells J, Warfield KL, Swenson DL, Welch LS, Sazani P, Wong M, Berry D, Kaye EM, Bavari S.

N Engl J Med. 2015 Jul 23;373(4):339-48. doi: 10.1056/NEJMoa1410345.

18.

Evaluation of Ebola Virus Inhibitors for Drug Repurposing.

Madrid PB, Panchal RG, Warren TK, Shurtleff AC, Endsley AN, Green CE, Kolokoltsov A, Davey R, Manger ID, Gilfillan L, Bavari S, Tanga MJ.

ACS Infect Dis. 2015 Jul 10;1(7):317-26. doi: 10.1021/acsinfecdis.5b00030. Epub 2015 May 11.

PMID:
27622822
19.

A single phosphorodiamidate morpholino oligomer targeting VP24 protects rhesus monkeys against lethal Ebola virus infection.

Warren TK, Whitehouse CA, Wells J, Welch L, Heald AE, Charleston JS, Sazani P, Reid SP, Iversen PL, Bavari S.

mBio. 2015 Feb 10;6(1). pii: e02344-14. doi: 10.1128/mBio.02344-14.

20.

Euthanasia assessment in ebola virus infected nonhuman primates.

Warren TK, Trefry JC, Marko ST, Chance TB, Wells JB, Pratt WD, Johnson JC, Mucker EM, Norris SL, Chappell M, Dye JM, Honko AN.

Viruses. 2014 Nov 24;6(11):4666-82. doi: 10.3390/v6114666.

21.

Rational design of small molecules as vaccine adjuvants.

Wu TY, Singh M, Miller AT, De Gregorio E, Doro F, D'Oro U, Skibinski DA, Mbow ML, Bufali S, Herman AE, Cortez A, Li Y, Nayak BP, Tritto E, Filippi CM, Otten GR, Brito LA, Monaci E, Li C, Aprea S, Valentini S, Calabrό S, Laera D, Brunelli B, Caproni E, Malyala P, Panchal RG, Warren TK, Bavari S, O'Hagan DT, Cooke MP, Valiante NM.

Sci Transl Med. 2014 Nov 19;6(263):263ra160. doi: 10.1126/scitranslmed.3009980.

22.

Filovirus RefSeq entries: evaluation and selection of filovirus type variants, type sequences, and names.

Kuhn JH, Andersen KG, Bào Y, Bavari S, Becker S, Bennett RS, Bergman NH, Blinkova O, Bradfute S, Brister JR, Bukreyev A, Chandran K, Chepurnov AA, Davey RA, Dietzgen RG, Doggett NA, Dolnik O, Dye JM, Enterlein S, Fenimore PW, Formenty P, Freiberg AN, Garry RF, Garza NL, Gire SK, Gonzalez JP, Griffiths A, Happi CT, Hensley LE, Herbert AS, Hevey MC, Hoenen T, Honko AN, Ignatyev GM, Jahrling PB, Johnson JC, Johnson KM, Kindrachuk J, Klenk HD, Kobinger G, Kochel TJ, Lackemeyer MG, Lackner DF, Leroy EM, Lever MS, Mühlberger E, Netesov SV, Olinger GG, Omilabu SA, Palacios G, Panchal RG, Park DJ, Patterson JL, Paweska JT, Peters CJ, Pettitt J, Pitt L, Radoshitzky SR, Ryabchikova EI, Saphire EO, Sabeti PC, Sealfon R, Shestopalov AM, Smither SJ, Sullivan NJ, Swanepoel R, Takada A, Towner JS, van der Groen G, Volchkov VE, Volchkova VA, Wahl-Jensen V, Warren TK, Warfield KL, Weidmann M, Nichol ST.

Viruses. 2014 Sep 26;6(9):3663-82. doi: 10.3390/v6093663.

23.

Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430.

Warren TK, Wells J, Panchal RG, Stuthman KS, Garza NL, Van Tongeren SA, Dong L, Retterer CJ, Eaton BP, Pegoraro G, Honnold S, Bantia S, Kotian P, Chen X, Taubenheim BR, Welch LS, Minning DM, Babu YS, Sheridan WP, Bavari S.

Nature. 2014 Apr 17;508(7496):402-5. doi: 10.1038/nature13027. Epub 2014 Mar 2.

PMID:
24590073
24.

Virus nomenclature below the species level: a standardized nomenclature for filovirus strains and variants rescued from cDNA.

Kuhn JH, Bào Y, Bavari S, Becker S, Bradfute S, Brauburger K, Rodney Brister J, Bukreyev AA, Caì Y, Chandran K, Davey RA, Dolnik O, Dye JM, Enterlein S, Gonzalez JP, Formenty P, Freiberg AN, Hensley LE, Hoenen T, Honko AN, Ignatyev GM, Jahrling PB, Johnson KM, Klenk HD, Kobinger G, Lackemeyer MG, Leroy EM, Lever MS, Mühlberger E, Netesov SV, Olinger GG, Palacios G, Patterson JL, Paweska JT, Pitt L, Radoshitzky SR, Ryabchikova EI, Saphire EO, Shestopalov AM, Smither SJ, Sullivan NJ, Swanepoel R, Takada A, Towner JS, van der Groen G, Volchkov VE, Volchkova VA, Wahl-Jensen V, Warren TK, Warfield KL, Weidmann M, Nichol ST.

Arch Virol. 2014 May;159(5):1229-37. doi: 10.1007/s00705-013-1877-2. Epub 2013 Nov 5.

25.

Discussions and decisions of the 2012–2014 International Committee on Taxonomy of Viruses (ICTV) Filoviridae Study Group, January 2012–June 2013.

Bukreyev AA, Chandran K, Dolnik O, Dye JM, Ebihara H, Leroy EM, Mühlberger E, Netesov SV, Patterson JL, Paweska JT, Saphire EO, Smither SJ, Takada A, Towner JS, Volchkov VE, Warren TK, Kuhn JH.

Arch Virol. 2014 Apr;159(4):821-30.

26.

Small molecule inhibitors of ER α-glucosidases are active against multiple hemorrhagic fever viruses.

Chang J, Warren TK, Zhao X, Gill T, Guo F, Wang L, Comunale MA, Du Y, Alonzi DS, Yu W, Ye H, Liu F, Guo JT, Mehta A, Cuconati A, Butters TD, Bavari S, Xu X, Block TM.

Antiviral Res. 2013 Jun;98(3):432-40. doi: 10.1016/j.antiviral.2013.03.023. Epub 2013 Apr 8.

27.

A systematic screen of FDA-approved drugs for inhibitors of biological threat agents.

Madrid PB, Chopra S, Manger ID, Gilfillan L, Keepers TR, Shurtleff AC, Green CE, Iyer LV, Dilks HH, Davey RA, Kolokoltsov AA, Carrion R Jr, Patterson JL, Bavari S, Panchal RG, Warren TK, Wells JB, Moos WH, Burke RL, Tanga MJ.

PLoS One. 2013;8(4):e60579. doi: 10.1371/journal.pone.0060579. Epub 2013 Apr 5.

28.

Characterization of a putative filovirus vaccine: virus-like particles.

Martins KA, Warren TK, Bavari S.

Virol Sin. 2013 Apr;28(2):65-70. doi: 10.1007/s12250-013-3306-9. Epub 2013 Feb 6. Review.

PMID:
23385315
29.

Virus nomenclature below the species level: a standardized nomenclature for laboratory animal-adapted strains and variants of viruses assigned to the family Filoviridae.

Kuhn JH, Bao Y, Bavari S, Becker S, Bradfute S, Brister JR, Bukreyev AA, Caì Y, Chandran K, Davey RA, Dolnik O, Dye JM, Enterlein S, Gonzalez JP, Formenty P, Freiberg AN, Hensley LE, Honko AN, Ignatyev GM, Jahrling PB, Johnson KM, Klenk HD, Kobinger G, Lackemeyer MG, Leroy EM, Lever MS, Lofts LL, Mühlberger E, Netesov SV, Olinger GG, Palacios G, Patterson JL, Paweska JT, Pitt L, Radoshitzky SR, Ryabchikova EI, Saphire EO, Shestopalov AM, Smither SJ, Sullivan NJ, Swanepoel R, Takada A, Towner JS, van der Groen G, Volchkov VE, Wahl-Jensen V, Warren TK, Warfield KL, Weidmann M, Nichol ST.

Arch Virol. 2013 Jun;158(6):1425-32. doi: 10.1007/s00705-012-1594-2. Epub 2013 Jan 29. No abstract available.

30.

Ebola virus genome plasticity as a marker of its passaging history: a comparison of in vitro passaging to non-human primate infection.

Kugelman JR, Lee MS, Rossi CA, McCarthy SE, Radoshitzky SR, Dye JM, Hensley LE, Honko A, Kuhn JH, Jahrling PB, Warren TK, Whitehouse CA, Bavari S, Palacios G.

PLoS One. 2012;7(11):e50316. doi: 10.1371/journal.pone.0050316. Epub 2012 Nov 28.

31.

Discovery and early development of AVI-7537 and AVI-7288 for the treatment of Ebola virus and Marburg virus infections.

Iversen PL, Warren TK, Wells JB, Garza NL, Mourich DV, Welch LS, Panchal RG, Bavari S.

Viruses. 2012 Nov 6;4(11):2806-30. doi: 10.3390/v4112806.

32.

Virus nomenclature below the species level: a standardized nomenclature for natural variants of viruses assigned to the family Filoviridae.

Kuhn JH, Bao Y, Bavari S, Becker S, Bradfute S, Brister JR, Bukreyev AA, Chandran K, Davey RA, Dolnik O, Dye JM, Enterlein S, Hensley LE, Honko AN, Jahrling PB, Johnson KM, Kobinger G, Leroy EM, Lever MS, Mühlberger E, Netesov SV, Olinger GG, Palacios G, Patterson JL, Paweska JT, Pitt L, Radoshitzky SR, Saphire EO, Smither SJ, Swanepoel R, Towner JS, van der Groen G, Volchkov VE, Wahl-Jensen V, Warren TK, Weidmann M, Nichol ST.

Arch Virol. 2013 Jan;158(1):301-11. doi: 10.1007/s00705-012-1454-0. Epub 2012 Sep 23. No abstract available.

33.

Advanced morpholino oligomers: a novel approach to antiviral therapy.

Warren TK, Shurtleff AC, Bavari S.

Antiviral Res. 2012 Apr;94(1):80-8. doi: 10.1016/j.antiviral.2012.02.004. Epub 2012 Feb 14. Review.

PMID:
22353544
34.

Nonhuman primates as models for the discovery and development of ebolavirus therapeutics.

Shurtleff AC, Warren TK, Bavari S.

Expert Opin Drug Discov. 2011 Mar;6(3):233-50. doi: 10.1517/17460441.2011.554815.

PMID:
22647202
35.

Alkylated porphyrins have broad antiviral activity against hepadnaviruses, flaviviruses, filoviruses, and arenaviruses.

Guo H, Pan X, Mao R, Zhang X, Wang L, Lu X, Chang J, Guo JT, Passic S, Krebs FC, Wigdahl B, Warren TK, Retterer CJ, Bavari S, Xu X, Cuconati A, Block TM.

Antimicrob Agents Chemother. 2011 Feb;55(2):478-86. doi: 10.1128/AAC.00989-10. Epub 2010 Dec 6.

36.

Advanced antisense therapies for postexposure protection against lethal filovirus infections.

Warren TK, Warfield KL, Wells J, Swenson DL, Donner KS, Van Tongeren SA, Garza NL, Dong L, Mourich DV, Crumley S, Nichols DK, Iversen PL, Bavari S.

Nat Med. 2010 Sep;16(9):991-4. doi: 10.1038/nm.2202. Epub 2010 Aug 22.

PMID:
20729866
37.

Antiviral activity of a small-molecule inhibitor of filovirus infection.

Warren TK, Warfield KL, Wells J, Enterlein S, Smith M, Ruthel G, Yunus AS, Kinch MS, Goldblatt M, Aman MJ, Bavari S.

Antimicrob Agents Chemother. 2010 May;54(5):2152-9. doi: 10.1128/AAC.01315-09. Epub 2010 Mar 8.

38.

Chemical modifications of antisense morpholino oligomers enhance their efficacy against Ebola virus infection.

Swenson DL, Warfield KL, Warren TK, Lovejoy C, Hassinger JN, Ruthel G, Blouch RE, Moulton HM, Weller DD, Iversen PL, Bavari S.

Antimicrob Agents Chemother. 2009 May;53(5):2089-99. doi: 10.1128/AAC.00936-08. Epub 2009 Feb 17.

39.

Immune responses to the smallpox vaccine given in combination with ST-246, a small-molecule inhibitor of poxvirus dissemination.

Grosenbach DW, Jordan R, King DS, Berhanu A, Warren TK, Kirkwood-Watts DL, Tyavanagimatt S, Tan Y, Wilson RL, Jones KF, Hruby DE.

Vaccine. 2008 Feb 13;26(7):933-46. doi: 10.1016/j.vaccine.2007.11.095. Epub 2007 Dec 26.

40.

Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge.

Berhanu A, Wilson RL, Kirkwood-Watts DL, King DS, Warren TK, Lund SA, Brown LL, Krupkin AK, Vandermay E, Weimers W, Honeychurch KM, Grosenbach DW, Jones KF, Hruby DE.

J Virol. 2008 Apr;82(7):3517-29. doi: 10.1128/JVI.01854-07. Epub 2008 Jan 16.

41.
42.

Listeria monocytogenes 10403S HtrA is necessary for resistance to cellular stress and virulence.

Wilson RL, Brown LL, Kirkwood-Watts D, Warren TK, Lund SA, King DS, Jones KF, Hruby DE.

Infect Immun. 2006 Jan;74(1):765-8.

43.

Identification and characterization of potent small molecule inhibitor of hemorrhagic fever New World arenaviruses.

Bolken TC, Laquerre S, Zhang Y, Bailey TR, Pevear DC, Kickner SS, Sperzel LE, Jones KF, Warren TK, Amanda Lund S, Kirkwood-Watts DL, King DS, Shurtleff AC, Guttieri MC, Deng Y, Bleam M, Hruby DE.

Antiviral Res. 2006 Feb;69(2):86-97. Epub 2005 Nov 28.

PMID:
16343651
44.
45.

Biological consequences of antigen and cytokine co-expression by recombinant Streptococcus gordonii vaccine vectors.

Byrd CM, Bolken TC, Jones KF, Warren TK, Vella AT, McDonald J, King D, Blackwood Z, Hruby DE.

Vaccine. 2002 May 22;20(17-18):2197-205.

PMID:
12009273
46.

Fewer T lymphocytes and decreased pulmonary influenza virus burden in mice exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD).

Lawrence BP, Warren TK, Luong H.

J Toxicol Environ Health A. 2000 Sep 15;61(1):39-53.

PMID:
10990162

Supplemental Content

Loading ...
Support Center